source
- Lilly reports 79% response rate for FRα-directed ADC in platinum-sensitive ovarian cancerLilly presented phase 1 data on its FRα‑directed antibody‑drug conjugate, sofetabart mipitecan (Sofe-M), combined with bevacizumab in patients whose ovarian cancer had progressed after platinum the…
- Merck acquires Silence Therapeutics for $1.3B; Hansoh Pharma signs $15B deal with RocheGerman Merck announced the acquisition of Silence Therapeutics in a transaction valued at $1.3 billion. In China, Hansoh Pharma disclosed a partnership with Roche that involves a $15 billion drug…